Compound · clinical trials

IBI3003 clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 4 trials in our China, USA and Australia registers that name IBI3003 as an intervention. Synced 9 Nov 2026

4Current trials

3Recruiting now

2Lead sponsors

3Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

IBI3003 is named as an intervention in 4 current clinical trials in our China, USA and Australia registers. 3 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Innovent Biologics (Suzhou) Co. Ltd (3). The most-studied condition is Multiple Myeloma.

Patient leaflets for IBI3003

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting375%
Not yet open125%

Trials by phase

Phase 1/2250%
Phase 2125%
Phase 3125%

Clinical trials of IBI3003

4 trials

Study	Phase	Status	Lead sponsor	Registers
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma	Phase 3	Recruiting	Innovent Biologics (Suzhou) Co. Ltd	China
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma NCT06083207 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Recruiting	Innovent Biologics (Suzhou) Co. Ltd	China, Australia
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma NCT07336472 · Multiple Myeloma	Phase 1/2	Recruiting	Fortvita Biologics (USA)Inc	USA
A Open-Label Phase in Participants With Multiple Myeloma NCT07764861 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Not yet open	Innovent Biologics (Suzhou) Co. Ltd	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with IBI3003

2 conditions

Multiple Myeloma3 Relapsed or Refractory Multiple Myeloma1

By country register

Register	Trials	Recruiting
Clinical trials in China	3	2
Clinical trials in USA	1	1
Clinical trials in Australia	1	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about IBI3003 trials

How many clinical trials are testing IBI3003?

4 current trials in our China, USA and Australia registers name IBI3003 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are IBI3003 trials recruiting patients?

Yes. 3 of the 4 trials are recruiting: 2 with sites in China, 1 with sites in USA and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors IBI3003 clinical trials?

Innovent Biologics (Suzhou) Co. Ltd (3) and Fortvita Biologics (USA)Inc (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IBI3003 works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IBI3003 works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IBI3003 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.